Independent pharmacies across the U.S. are running into a wall with the Drug Chain Secuirty Act (DSCSA). The law now brings wholesalers fully into scope and changes how pharmacies must electronically receive and reconcile serialized shipments. Each unit carries a unique serial identifier, supported by interoperable digital transaction data that trace its path from manufacturer to pharmacy shelf. It is good for safety but hard on small teams. Chain pharmacies manage this transition with scale. They have integrated systems, a dedicated compliance staff, and a budget to maintain scanners, portals, and data storage. However, independent owners do not have that leverage since they are the pharmacist, the buyer, and the IT support all in one. A single mismatched data reconciliation can stop a shipment from being received. Incomplete or mismatched data files trigger exceptions that take time to fix. And since verification tools are still evolving, pedigree checks often add more delays than answers. What independent pharmacies need is simple. They need products that arrive already validated and easy to confirm. They also need a distributor that sources what big systems overlook, such as niche strengths and specialty generics that matter in real clinics. That kind of support does more than fix logistics. It keeps the personal side of pharmacy alive, where care is local, names are remembered, and patients are more than profiles. That is the belief that drives True Marker Pharmaceuticals. The company is a national wholesaler built around the realities of independent pharmacies. It treats compliance as part of daily work, not an added burden. Each shipment is processed in accordance with DSCSA serialization and verification requirements, so by the time it reaches the counter, pharmacists can stay focused on what matters most—the people they serve. “Independent pharmacies shouldn’t have to choose between meeting DSCSA requirements and serving their patients. We have built our distribution systems so that compliance happens quietly in the background, allowing pharmacists to keep doing what they do best while we handle the rest,” says Davin Deb, CEO..

Stem cell storage at birth is a once-in-a-lifetime decision. Parents want the confidence that their child’s cells will remain clinically viable if ever needed. That trust depends on more than storage—it relies on medical experience, transparent operations, full licensing, and a proven record of therapeutic use. With more than 25 years of continuous operation and its oldest German facility, Vita34, nearing 30 years, FamiCord is Europe’s largest family stem cell banking group and the only publicly listed company in this field. It gives families assurance through transparency and long-term realibility, confirming FamiCord as the best choice in Europe for stem cell banking. The company offers a complete system that guides parents from collection to processing, long-term preservation, and eventual release of cord blood and perinatal tissue for treatment. Each step is anaged under strict medical and regulatory standards to ensure cells retain therapeutic potential, with a documented chain of custody, validated cold-chain transport, and laboratory checks for viability and sterility. This matters because gobally, hematopoietic stem cells from cord blood have been used in more than 60,000 transplants across 80 diseases, and 158 ongoing clinical trials continue to refine indications and delivery. Regenerative medicine is rapidly opening new uses for cord blood and cord tissue. Beyond hematology, cord blood contains immuno- and neuroactive cell subsets under study for autism, cerebral palsy, neurodegeneration, autoimmune and cardiovascular conditions, with 140 active clinical trials worldwide. “We are not simply a bank of stem cells. A bank only stores the material, but it is really about whether you ever can deploy the stem cells for a transplant or therapy. We are glad we have that experience,” says Tomasz Baran, MD, Chief Medical Officer. Strength Through Structure and Innovation FamiCord operates under licensed medical service frameworks across major European markets, ensuring full national regulatory compliance and external oversight. About half of its 15 laboratories hold AABB accreditation, one of two international standards for cord blood standards in banking. As EBMT member, FamiCord aligns with Europe’s bone marrow transplant and cell therapies community. Scale, application experience, and transparency are core strengths. As Europe’s only publicly listed stem cell bank, FamiCord provides families and partners with full transparency into its financial stability—aligned with the long-term horizons of stem cell preservation. In 2024 FamiCord expanded beyond Europe, opening its first lab in Dubai-quickly earning AABB accreditation, applying standards established in European operations. Regional names such as Smart Cells (UK and Dubai) and Vita 34 (DACH region) now operate under the FamiCord umbrella, helping clinicians and parents recognize that a single, regulated organization stands behind the service..